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Therapeutic approaches aimed at curing prostate cancer are only partially successful given the occurrence of
highly metastatic resistant phenotypes that frequently develop in response to therapies. Recently, we have
described αvβ6, a surface receptor of the integrin family as a novel therapeutic target for prostate cancer; this
epithelial-specific molecule is an ideal target since, unlike other integrins, it is found in different types of cancer
but not in normal tissues.
We describe a novel αvβ6-mediated signaling pathway that has profound effects on the microenvironment.
We show that αvβ6 is transferred from cancer cells to monocytes, including β6-null monocytes, by exosomes
and that monocytes from prostate cancer patients, but not from healthy volunteers, express αvβ6. Cancer cell
exosomes, purified via density gradients, promote M2 polarization, whereas αvβ6 down-regulation in
exosomes inhibits M2 polarization in recipient monocytes. Also, as evaluated by our proteomic analysis, αvβ6
down-regulation causes a significant increase in donor cancer cells, and their exosomes, of two molecules
that have a tumor suppressive role, STAT1 and MX1/2. Finally, using the Ptenpc−/− prostate cancer mouse
model, which carries a prostate epithelial-specific Pten deletion, we demonstrate that αvβ6 inhibition in vivo
causes up-regulation of STAT1 in cancer cells.
Our results provide evidence of a novel mechanism that regulates M2 polarization and prostate cancer
progression through transfer of αvβ6 from cancer cells to monocytes through exosomes.
© 2017 Elsevier B.V. All rights reserved.r B.V. All rights reserved. Matrix Biol. (2017) xx, xxx-xxx
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Prostate cancer is one of the leading causes of
cancer-related deaths among men in the United
States [1]. The disease has heterogeneous growth
patterns, and its prognosis is poor when it becomes
metastatic [2] or androgen-independent (castrate-
resistant prostate cancer, CRPC), which remains
incurable with elevatedmorbidity andmortality. These
features highlight the pressing urgency for a better
mechanistic understanding of pathways of prostate
cancer progression [3,4].
Signaling mediated by the integrin family of cell
adhesion receptors has been implicated as a
mechanistic driver of this disease [5–8]. Integrins
are transmembrane cell adhesion receptors that are
comprised of one α and one β subunit; these
molecules play a key role in cellular homeostasis
in normal tissues, and become de-regulated in a
variety of epithelial malignancies, including prostate
cancer progression to advanced disease stages
[9–12], where they promote cell survival, adhesion,
proliferation, and modulation of invasive phenotypes
[6,10]. In particular, the epithelial-specific αvβ6 integ-
rin, not detectable in the normal prostate of humans or
mice, is expressed at high levels in cancer [13,14].
Taken together, these results support a pivotal role of
αvβ6 as an important therapeutic target in advanced
prostate cancer. Another αv-containing integrin, αvβ3,
present in normal prostate at low levels, is up-
regulated in primary and metastatic prostate cancer
[9,10,15], but unlikeαvβ6,αvβ3promotes osteoblastic
metastasis [16]. The αvβ6 integrin is localized in focal
contacts, and functionally, mediates adhesion to
fibronectin as well as latency associated peptide
(LAP)-TGFβ1, promoting the release of active TGFβ1,
which functions as a pro-metastatic cytokine [17], as
well as an osteolytic program in prostate cancer cells
[18]. The αvβ6 integrin promotes tumor growth in vivo
as shown by others and us and is shown to be a
therapeutic target in breast cancer and prostate
cancer [14,19]. Finally, αvβ6 correlates with poor
survival in breast [19], cervical [20] and colorectal [21]
cancer.
Very recently, we and others have shown that
integrins, which are transmembrane glycoproteins
deregulated in cancer [5,9,22], as well as other
bioactive molecules, basement membrane assem-
bly [23] or specific subunits partaking in a number of
diverse of key roles [24–28] are found in extracellular
vesicles (EVs), including exosomes. These EVs
mediate interactions between the tumor, tumor
microenvironment (TME) and extracellular matrix
(ECM). Specifically, we have published that the αvβ6
integrin is transferred from cancer cells to recipient
cells via exosomes and remains active in these cells
[29]. Exosomes are small (50–150 nm) EVs present
in blood, urine and the medium of cultured cells [30],
different from oncosomes also found in prostatePlease cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009cancer [31,32]. The field of exosome research is a
fast growing area of investigation, and in the past
decade exosomes have emerged as important
mediators of intercellular communication, frequently
involved in malignancy [29,33]. Exosomes have
been shown in the serum of patients harboring a
variety of tumors, correlating with advanced disease
stages; their number in human blood is very abun-
dant with specific subsets increased in cancer [34].
There is evidence that exosomes released from
cancer cells promote a pro-metastatic phenotype
through extracellular matrix remodeling [35,36], and
a potential role of integrins packaged in tumor-
released exosomes, in mediating advanced disease
traits, has only recently begun to emerge [33,37].
Given the failure of ipilimumab (an antibody that
binds CTLA4) to improve survival in prostate cancer
patients and the paucity of T cells in prostate cancer
tissues [38], recent work has begun to investigate
the possibility that macrophages may be key players
in prostate cancer progression. In cancer, macro-
phages can exert both anti- and pro-tumoral func-
tions. Macrophages are heterogeneous cells with
high plasticity representing a wide spectrum of
activation states, ranging from the classically acti-
vated M1 macrophages to several subsets
of alternatively activated M2 macrophage. Anti-
inflammatory M2 macrophages are better adapted
to scavenging debris and releasing growth factors
that promote angiogenesis and fibrosis [39]. Even
still highly phagocytic, the major role of M2 macro-
phages is helping with repair of injuries by engulfing
cell debris, regulating tissue re-modeling, and
promoting normal cell turnover [40]. ECM pathways
mediate M2 polarization, as shown in kidney
whereby homogenization of renal ECM structure
induces instead M1 macrophage polarization sug-
gesting an important role of the 3D architecture [41].
Activation to M2 macrophages can occur through
a variety of signals, including those mediated by
cytokines including IL-4, IL-10, IL-13 and TGFβ, and
can be promoted by the presence of glucocorticoid
hormones [42]. Tumor-associated macrophages
(TAMs) are the major component of the immune
infiltrate of the stroma of solid tumors, representing
up to 50% of the tumor mass where they can play a
key role in tumor development [43,44]. TAMs are
evidently educated by the TME in that they generally
acquire the hallmarks of M2 macrophages, with their
associated anti-inflammatory, immune modulatory,
and angiogenic properties that promote tissue remod-
eling [45]. Different subsets of M2 macrophages
produce IL-10, TGFβ, VEGF as well as various
combinations of certain factors more often associated
with a classical pro-inflammatory M1 macrophage
subset. Among the M2 phenotypic markers shared
by TAM are the scavenger receptors CD163, CD204,
CD206, and Arg-1 as well as classical macrophage
markers. A team led by Dr. Pienta has promoted theired for monocyte M2 polarization in prostate cancer, Matrix Biol
3αvβ6 Integrin Promotes M2 Polarizationidea that macrophages support prostate cancer
tumorigenicity via CCL2, a chemokine known to
recruit monocytes and macrophages to sites of
inflammation in tumor beds [46].
Our data demonstrate that αvβ6 has profound
effects on the TME. Specifically, we show that αvβ6
prevents the induction of the STAT1/MX1/2 signaling
pathway in cancer cells and their exosomes, and
that its down-regulation or inhibition in vivo in cancer
exosomes inhibits the polarization of monocytes
toward a M2 phenotype and causes up-regulation
of the M2 inhibitor interferon-γ pathway. This study
indicates that inhibition of this integrin and its down-
stream effectors might offer a novel immune – based
therapeutic strategy in prostate cancer.Please cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009Results
αvβ6-positivecancercell exosomesare transferred
to peripheral blood mononuclear cells (PBMC)
We have previously shown that the αvβ6 integrin
is shed by prostate cancer cells packaged in EVs
which, in turn, transfer this integrin to recipient αvβ6
negative cancer cells [29]. We hypothesized that this
transfer to αvβ6 negative cells in the microenviron-
ment amplifies the signals mediated by αvβ6 in the
tumor. To test this hypothesis, we selected peripheral
blood mononuclear cells (PBMC) as recipient cells
due to their content of monocytes, the precursors ofFig. 1. Exosomal αvβ6 is transferred from
prostate cancer cells to PBMC. (A), Left,
nanoparticle size distribution analysis of PC3
exosomes (Exo) by NTA. Right, IB analysis of β6
integrin, exosomal markers CD63, CD81 and
calnexin (CANX) in lysates of PC3 Exo and cells
(TCL). (B), PBMC (3.0 × 105 cells) derived from
β6-null mice (pool of 3 mice) were incubated with
PC3 Exo (30 μg/mL at a concentration of 2.4 ×
109 vesicles/μg) for 24 h. The cells were washed
with acid wash buffer twice followed by IB
analysis of cell lysates for expression of β6
integrin and actin (loading control). (C), PBMC
(3.0 × 105 cells) from two different human
healthy donors were incubated with indicated
PC3 Exo concentrations (0, 12, 30 μg/mL at a
concentration of 2.4 × 109 vesicles/μg) for 24 h
and cell lysates were analyzed by IB for
expression of β6 integrin and actin (loading
control). (D), THP1 cells (3.0 × 105 cells) were
incubated with the indicated PC3 Exo concentra-
tions (0, 30, 60 μ/mL at a concentration of 2.4 ×
109 vesicles/μg) for 24 and 48 h and analyzed
by IB for expression of β6 integrin and actin
(loading control).
ired for monocyte M2 polarization in prostate cancer, Matrix Biol
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ferential centrifugation at 100 Kg as previously de-
scribed [47]; then, characterized the EV using the
following approaches: NTA, which confirmed that
the majority of the EVs have a size of 130–150 nm;
immunoblotting (IB), which shows the characteristic
exosomal enrichment in CD63 and CD81 (Fig. 1) and
by iodixanol density gradient separation (Fig. 2).
Therefore, the isolated EVs are designated exosomes
in our study. Routine IB analysis also shows that
these exosomes do not express calnexin (CANX), an
endoplasmic reticulum (ER) marker (Fig. 1A).
We incubated PC3 cell exosome preparations
with PBMC isolated from β6-null mice (Fig. 1B). The
PBMC, isolated from β6-null mice were 5.58%mono-
cytes and 88.4% lymphocytes. The majority of the
gated monocytes are CD11b-positive (Fig. S1). TheFig. 2. Transfer of GFP-tagged αvβ6 integrin to PBMC. (A)
marker CD9 in parental PC3, EGFP-PC3 (Mock) and β6-EGF
(TCL). (B), Left, Iodixanol gradient analysis of β6-EGFP-PC3 de
Procedures. Expression of β6, CD63, and CD81 analyzed
1.11–1.14 g/mL. Right, NTA for the fifth fraction (density 1.14 g
Exo is shown. (C), Left, human normal PBMC (2.0 × 105 cells) i
immuno-stained for CD14. Flow cytometric contour plots of c
cytometric analysis of comparative expression of GFPmeasure
with parental PC3 or β6-EGFP-PC3 Exo (8 μg/mL for 36 h). R
CD163 (M2 macrophage marker) measured as MFI in PBMC
Two graphs showing GFP and CD163 MFI include data from
**: p b 0.01, student's t-test.
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(Fig. 1B) show that β6 is transferred to these cells
and confirm that the expression of β6 integrin in the
PBMC is not the result of endogenous β6 integrin
synthesis. Furthermore, the results show that acid
wash only slightly reduced β6 levels transferred
to PBMC, indicating that the newly detected αvβ6
levels are not due to exosome attachment to the
cell surface. Finally, we tested whether PBMC from
two healthy donors or THP1 cells would express
β6 integrin upon incubation with exosomes isolated
from PC3 cells. The results show that β6 is trans-
ferred to PBMC isolated from healthy donors (n = 5,
Fig. 1C) and THP1 cells (Fig. 1D). The results
also show that exosome transfer to PBMC occurs
in a concentration-dependent manner and reaches
a plateau at 24 h. Furthermore, we transfected β6-, IB analysis for expression of GFP, CANX and exosomal
P-PC3 derived exosome lysate (Exo) and total cell lysate
rived Exo was performed as described in the Experimental
by IB is shown. The expected density range for Exo is
/mL) from the iodixanol gradient of β6-EGFP-PC3 derived
ncubated with 8 μg/mL of β6-EGFP-PC3 Exo for 36 h, were
ells gated as CD14+ monocytes are shown. Middle, flow
d as mean fluorescence intensity (MFI) in PBMC incubated
ight, flow cytometric analysis of comparative expression of
incubated with or without parental PC3 (8 μg/mL for 36 h).
4 biological replicates tested in 2 different experiments.
ired for monocyte M2 polarization in prostate cancer, Matrix Biol
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these cells first by differential centrifugation at 100 Kg
[29,48] and then by iodixanol gradient separation.
The preparations obtained by differential centrifu-
gation at 100 Kg do not express CANX whereas
they express CD9 (Fig. 2A); the fused β6-EGFP
is detected at 150 KD, while the EGFP is at 25 KD.
The αvβ6 positive exosomes, purified on an iodixanol
density gradient, contain the exosomal markers
CD63 and CD81 in fraction 5 (density = 1.14 g/mL)
and have an average size of 100 nm (Fig. 2B).
Finally, we incubated these purified exosomes with
human PBMC isolated from two healthy donors and
then, characterized the cells by FACS for CD14, GFP
and CD163 expression (Fig. 2C). Our FACS analysis
shows that GFP-β6 is found in CD14-positive PBMC
upon exosome incubation (Fig. 2C), but not in CD14-
negative cells (data not shown). Overall, these
results show that exosomal β6, shed by cancer
cells, is transferred to CD14-positive monocytes and
is associated with their expression of CD163.Fig. 3. αvβ6 integrin down-regulation in exosomes inhibi
(2.0 × 105 cells) derived from two healthy donors were incub
(Exo) (hi: 8 μg/mL; lo: 0.8 μg/mL) derived from PC3 cells incu
one of two different siRNAs specific to β6 mRNA (D1 or D
polarization analysis by flow cytometry. (A), Contour plots de
expression of M2 polarization markers CD163 and CD204
gated cells. (B), There are 4 different PBMC treatment group
from PC3 cells transfected with non-silencing siRNA; D1, P
with a β6-siRNA duplex designated D1; D2, PBMC treated w
β6-siRNA designated D2. Mean fluorescence intensity (MFI).
D1-hi, and D2-hi are statistically lower than NS, as assessed b
expression in TCL and Exo derived from PC3 cells transfecte
(FLOT1) was used as loading control for TCL and Exo, wherea
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inhibits M2 polarization of PBMC
The fact that CD14-positive PBMC acquire αvβ6
and CD163 upon incubation with exosomes con-
taining this integrin, led us to further examine the
effect of the exosomes on monocyte differentiation,
particularly since M2 polarization is known to pro-
mote tumor growth [43,44,49]. To more specifically
demonstrate that αvβ6 contributes to M2 polariza-
tion, we down-regulated αvβ6 in the PC3 cells using
siRNA, and isolated exosomes from these cells for
treatment of human normal PBMC. We used 4 dif-
ferent groups of PC3 cells, which were either not
incubated (–) or incubated with the following siRNA:
non-silencing (NS), or β6 integrin targeting siRNAs
(D1 or D2) [14,18,29]. A significantly lower percent-
age of CD14 gated-CD163+/CD204+ cells is ob-
served upon incubation of exosomes isolated from
αvβ6 down-regulated cells (7% vs. 35%) (Fig. 3A).
Fig. 3B shows that the expression of M2 polarizationts recipient monocyte M2 differentiation. Human PBMC
ated for 48 h with different concentrations of exosomes
bated with no siRNA, a non-silencing siRNA (NS) or with
2). Cultures were harvested at 48 h for M2 monocyte
pict live gating of CD14+ monocytes and representative
in this population. Numbers indicate the percentage of
s: untreated cells (−); NS, PBMC treated with exosomes
BMC treated with exosomes from PC3 cells transfected
ith exosomes from PC3 cells transfected with a different
The percentages of CD14 gated CD163+/CD204+ cells in
y Dunnett's test. **: p b 0.01. (C), IB analysis of β6 integrin
d with NS siRNA or with β6 siRNA (D1 and D2). Flotilin 1
s CANX was used as loading control for TCL but not Exo.
ired for monocyte M2 polarization in prostate cancer, Matrix Biol
6 αvβ6 Integrin Promotes M2 Polarizationspecific markers, CD163 andCD204 in normal CD14-
positive PBMC is moderately increased by incubation
with αvβ6 bearing exosomes isolated from PC3 cells
transfected with a non-silencing siRNA. In contrast,
treatment of the CD14-positive PBMCwith exosomes
from siRNA treated PC3 cells in which αvβ6 expres-
sion has been down-regulated, significantly reduces
CD163 and CD204 expression. Similar results are
obtained using either D1 or D2 siRNAs, two different
duplexes targeting β6-integrin [14,18]. IB analysis
shows an enrichment of β6 in exosomes as compared
to TCL in non-silencing controls, while a significant
reduction is observed in both TCL and exosomes
upon β6 siRNA treatment (Fig. 3C). The exosome
preparations utilized lack CANX (Fig. 3C).
Down-regulation of the αvβ6 integrin in PC3 cells
affects the exosomal proteome composition
We performed an extensive proteomic analysis
of PC3 exosome lysates. We purified exosomes
from these same 4 groups of cells described above
and performed a comparative label-free proteomic
analysis (2037 proteins). Unsupervised hierarchicalFig. 4. Proteomics analysis of Exosomes from PC3 cells up
STAT1 and MX1/2 proteins. (A) Results of a proteomics expe
cells treated with non-silencing siRNA (NS), or two β6 integrin
based on label-free quantification of protein intensities is shown
proteins are shown in this heat map. Red = higher, blue = lowe
for the proteins most significantly affected by D1 and D2, detec
Please cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009clustering of protein intensities demonstrates
dramatic differences between exosome proteomes
(Fig. 4A) using exosomes from non-treated cells
(NT) and cells treated with NS siRNA clustering
together, while exosomes from cells treated with
either D1 or D2 siRNA cluster together. Overall,
339 proteins are significantly affected by β6
integrin down-regulation (FDR b 10%) with the major-
ity of them being up-regulated in exosomes (n = 239,
79.7%).
The changes in protein abundance within exo-
somes are emphasized in our focused analysis
shown in Fig. 4B. In order to find proteins most
affected by the β6 integrin knockdown, we selected
only robustly detected candidates (at least 10 MS/
MS counts, 10 unique peptides) that significantly
changed (FDR b 10%) at least 4 fold. In-depth anal-
ysis shows that many signaling molecules from the
interferon-γ pathway which blocks M2 in favor of
M1 monocyte polarization such as STAT1, MX1, and
MX2 are increased upon β6 integrin down-regulation.
In fact, among all 239 proteins upregulated upon
αvβ6 knockdown, we find a significant enrichment of
proteins involved in interferon signaling (14 proteins,on β6 integrin knockdown reveals increased expression of
riment comparing exosomes from non-treated cells (NT),
siRNAs (D1 and D2). Unsupervised hierarchical clustering
. Each horizontal bar is a unique protein and a total of 2037
r protein abundance. (B) Heatmap of relative protein levels
ted with at least 10 MS/MS counts and 10 unique peptides.
ired for monocyte M2 polarization in prostate cancer, Matrix Biol
7αvβ6 Integrin Promotes M2 Polarization26 fold more than expected by chance, p = 1 × 10−10
byFisher Exact test).MX1 levels are themost affected
followed by MX2 and STAT1; they increased respec-
tively: 838 fold, 22 and 5.2 fold. Enrichment of STAT1
in PC3 exosomes in which αvβ6 has been down-
regulated appears to be specific since the levels of
EGFR, another molecule known to activate STAT1
[50], do not show significant up-regulation (down-
regulated 1.4 fold, p = 0.094). In contrast, Protein
inhibitor of activated STAT1 (PIAS1), which inhibits
STAT1-mediated gene activation [51] and is in-
creased in prostate cancer [52], is detected in cells
but not in exosomes, although the levels were not
changed upon αvβ6 down-regulation.
STAT1 levels in cells and exosomes increase
upon αvβ6 integrin down-regulation
The proteomic results were validated by IB anal-
ysis and show that STAT1 accumulates in cells and
consequently in exosomes upon down-regulation
of β6 by siRNA (Fig. 5A and B); and that MX1/2
accumulates just in exosomes upon down-regulation
of β6 (Fig. 5C). TSG101 (Fig. 5A, bottom), CD81,
CD63 (Fig. 5B) and CD9 (Fig. 5B and C) are used as
exosomal markers, whereas ERK (Fig. 5A, top) and
CANX (Fig. 5B and C) are used as loading controls
for TCL. As expected, the levels of CD81, CD9 and
CD63 are highly enriched in the exosome prepara-Fig. 5. β6 integrin down-regulation results in increased exp
(A), IB analysis of STAT1 expression in 30 μg of exosome lysa
incubated either with a non-silencing siRNA (NS siRNA) or wit
loading control for TCL and TSG101 was used as loading co
exosomal markers CD81, CD9, CD63 in PC3 cell Exo lysate a
siRNA or with D1 and D2 siRNA. CANX was used as loading
expression of β6 integrin and MX1/2 in TCL and Exo derived fro
shβ5 retroviral constructs. PC3-shβ5 transfectants are used as
TCL and CD9 was used as a loading control for Exo lysates.
Please cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
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the exosome preparations confirms the purity of the
isolated exosome fractions (Fig. 5C).
The results in Fig. 5C indicate that packaging
of STAT1 into exosomes is likely a reflection of
increased STAT1, but not MX1/2, levels in the cells.
However, the proteomic results were also validated
by IB analysis upon blocking of β6 by 6.3G9 a
monoclonal antibody (mAb) to αvβ6 and show that
STAT1 and MX1/2 accumulate in cells (Fig. 6A). The
6.3G9 Ab does not affect cell viability of prostate
epithelial cells, however, it does inhibit prostate cell
adhesion ([14] and data not shown).
These results obtained in vitro were validated in
vivo. We reported previously that αvβ6 is required
for prostate cancer growth in non-castrated and
castrated Ptenpc−/−mice, a well-established prostate
cancer model [14]. The tumor size was measured by
ultrasound before Ab injection. The average volume
of the tumor is 18.9 mm3 in 6.3G9 group, compared
with 18.2 mm3 in 1E6 group, the isotype control
mAb; t-test shows no significant difference in tumor
sizes between the 6.3G9 and 1E6 groups (data not
shown). Administration of 6.3G9, to Ptenpc−/− mice
results in acute disruption of epithelial layers of
prostate adenocarcinoma and in a significant de-
crease in tumor weight as compared with mice
treated with 1E6. In our previous study, 6.3G9 did not
show disruption of epithelial layers in normal glandsression of STAT1 and MX1/2 in PC3 cells and exosomes.
te (Exo) and total cell lysate (TCL) derived from PC3 cells
h β6 mRNA directed siRNA (D1 or D2). ERK was used as
ntrol for Exo lysate. (B), IB analysis of the expression of
nd TCL derived from PC3 cells incubated either with a NS
control found in TCL but not in Exo. (C), IB analysis of the
m parental PC3 cells or PC3 cells transfected with shβ6 or
a negative control. CANX was used as a loading control for
ired for monocyte M2 polarization in prostate cancer, Matrix Biol
Fig. 6. Inhibition of αvβ6 increases STAT1 levels in
prostate cancer cells and Ptenpc−/− mice. (A), Evalu-
ation of STAT1 and MX1/2 levels by IB in TCL from
PC3 cells either untreated or treated with αvβ6
monoclonal antibody 6.3G9 or isotype control anti-
body 1E6 (both at 10 μg/mL). Actin was used as
loading control. (B), Immunohistochemical analysis of
STAT1 and αvβ6 expression in prostate tumors from
Ptenpc−/−mice (sacrificed at 10–13 weeks) treatedwith
6.3G9 or 1E6 antibodies (10 mg/Kg/week × 5 weeks;
n = 5). Representative IHCandH&E imagesare shown
(Scale bar, 100 μm). Arrow, STAT1 expression in
nuclei of prostate tumor cells. Arrowhead, nuclei of
prostate tumor cells lacking STAT1 expression.
8 αvβ6 Integrin Promotes M2 Polarization[14]. In the current study, using Ptenpc−/− mice
treated with an Ab to αvβ6, 6.3G9, or 1E6, we show
that STAT1 accumulates in the αvβ6 expressing
cancer cells (Fig. 6B). In the 6.3G9 treated tumors,
65.1% malignant cells show STAT1 staining versus
only 17.9% in the 1E6 treated tumors (Fig. 6B).
To analyze the relevance of our observation that an
epithelial specific integrin, αvβ6, is transferred to
monocytes, we studied whether αvβ6 is expressed in
vivo in monocytes from cancer patients or tumor-
bearing mice. We first tested αvβ6 expression in
PBMC isolated fromwhole blood using the Lympholyte
density gradient from 14 prostate cancer patients
(including 8 CRPC patients). As control, PBMC from 5
healthy donors were used. The results in Fig. 7A show
a representative flow analysis. Expression of αvβ6 is
found in monocytes from 9 out of 14 prostate cancer
patients, and 6 out of the 8 CRPC patients, but not in
monocytes from healthy donors or lymphocytes from
either prostate cancer patients or healthy donors.Please cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009We then studied whether αvβ6 is expressed in
monocytes from tumor-bearing mice; as control,
PBMC from normal mice were used. For this analysis,
we tested αvβ6 expression in PBMC isolated from
whole blood using the Lympholyte density gradient
from 11Ptenpc−/−mice, and 9Ptenwild-typemice (Fig.
S2). Expression of αvβ6 is not found in monocytes
from normal mice although its expression levels are
variable (Fig. S2). As observed in human PBMC, αvβ6
is not detectable in lymphocytes fromPtenpc−/− or wild-
type mice, suggesting a monocyte specific uptake of
the αvβ6 exosomes.
In conclusion, based on our results, the model
proposed here in Fig. 7B is as follows: αvβ6-positive
or αvβ6-negative exosomes are released by cancer
cells and transferred to monocytes, thus respectively
supporting or, rather, preventing M2 polarization in
favor of M1 macrophage polarization. Conse-
quently, by down-regulating or inhibiting αvβ6 in
cancer cells, we expect that increased STAT1/ired for monocyte M2 polarization in prostate cancer, Matrix Biol
Fig. 7. αvβ6 Integrin is expressed in PBMC from prostate cancer patients. (A), Flow cytometric analysis of αvβ6
expression in PBMC from prostate cancer patients and healthy subjects. Left, monocytes and lymphocytes are gated by
SSC and FSC. Right, FACS analysis of αvβ6 cell surface expression in monocytes and lymphocytes from healthy subjects
and prostate cancer patients respectively, utilizing 6.3G9 monoclonal antibody to αvβ6 and mouse IgG, as isotype control.
Representative data are shown. (B), The schematic diagram shows that transfer of exosomal αvβ6 integrin from prostate
cancer cells to monocytes results in down-regulation of STAT1 and MX1/2 levels and increased M2 polarization of
monocytes, and has a pro-tumorigenic effect, whereas transfer of αvβ6 integrin–negative exosomes results in increased
M1 polarization of monocytes, and inhibits cancer growth.
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will be generated and an anti-tumor effect will be
obtained.Discussion
In this study, we demonstrate that the αvβ6
integrin has profound effects on the microenviron-
ment by preventing induction of the STAT1/MX1/2
signaling pathway in donor cancer cells and their
exosomes. In this regard, we show that αvβ6
positive exosomes are transferred to monocytes
and promote M2 monocyte polarization, whereas
exosomes from cancer cells, in which αvβ6 has
been down-regulated or inhibited, carry high levels
of STAT1/MX1/2 and inhibit M2. Finally, we
demonstrate that αvβ6 inhibition in vivo causes
up-regulation of the STAT1 signaling pathway in
cancer cells.
The effect of the αvβ6 integrin on STAT1 has
significant implications since STAT1 plays a critical
role in tumorigenesis by controlling a complex array
of activities and functions [53]. In response to
cytokines and growth factors, including interferon
(IFN)-alpha, IFN-gamma, EGF, PDGF and IL6,
STAT1 gets activated by receptor-associated ki-
nases and then forms homo- or heterodimers that
translocate to the nucleus and act as transcriptional
activators. In many types of tumors, STAT1 induces
anti-proliferative genes that directly block tumor
growth; it is generally considered as tumor suppres-
sor [54] given its ability to induce immune effector
genes which block cell cycle progression [55] or
inhibit angiogenesis [56]; in prostate cancer, loss
of STAT1 is associated with poor prognosis [57]. In
some instances, STAT1 promotes carcinogenesis
and tumor survival in particular tissues or as a result
of cross-talking with other signaling pathways [58];
however, its dominant effect is likely to promote
an anti-tumor immune response given its ability to
induce effector expression in immune cells [53]. The
effect of αvβ6 integrin on MX1/2 has also significant
implications since MX1 expression has been report-
ed to be dependent on STAT1 signaling [59], and
MX2, a member of the family of dynamin-like large
GTPases, is also interferon-inducible [60] and thus
plays a role in the immune response. Only a limited
number of studies have examined the role of MX1/2
in cancer [61,62]. MX1 expression has been shown
to inversely correlate with prostate cancer and gain
of MX1 expression in prostate cancer cells results
in cell cycle arrest [61]. Although limited in number,
these studies suggest a tumor suppressive role
for MX1/2 in prostate cancer. Therefore, by revealing
a cross-talk between cancer cells and monocytes
mediated by the exosomal αvβ6 and by its inhibitory
activity on the STAT1 - MX1/2 pathway, this study
indicates that inhibition of this integrin and its down-Please cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009stream effectors might offer a novel immune – based
therapeutic strategy in prostate cancer.
Finally, we demonstrate that in the absence of αvβ6,
tumor cell exosomes inhibit monocyte M2 polariza-
tion. This finding and the knowledge that M2 macro-
phages are often phenotypically and functionally
similar to TAM and support prostate cancer
tumorigenicity, provide a strong support for our
model (Fig. 7) which illustrates that transfer of
integrins, specifically of αvβ6, from cancer cells to
monocytes regulates monocyte M2 polarization.
The mechanism described here may have wider
significance for various types of cancer and may
explain how cross-talk between cancer cells and
surrounding normal cells, such as leukocytes, may
also be mediated by the uptake of exosomal
integrins.
Based on our novel mechanistic studies, showing
that transfer of exosomes from αvβ6-positive PC3 cells
to monocytes drives M2 polarization while transfer of
exosomes from αvβ6-negative PC3 cells causes
inhibition of M2 polarization, we propose that transfer
of integrins, specifically of αvβ6, or integrin–regulated
downstream effectors from cancer cells to monocytes
promotes prostate cancer progression toward a CRPC
phenotype. An additional innovative aspect is that we
show for the first time that cancer cell integrins control
monocyte response, an area that has begun to be
studied; so far, only one study on αvβ3 integrin's role in
leukocytes in breast cancer [63] has been published,
but a very different mechanism has been proposed
since the authors have studied αvβ3 endogenously
expressed in leukocytes. Furthermore, since in this
study, αvβ3 is shown to have an antitumor effect and
promoteM1 polarization and STAT1 activation, we can
speculate that β6 competes for β3 for binding to the αv
subunit and causes a M2 promoting effect. We have
reported previously that αvβ6 promotes prostate
cancer progression by activation of androgen receptor
(AR) in absence of androgen [14]. Androgen blockade
in tumor cells, either by castration or MDV 3100
treatment, induces the expression of macrophage
colony stimulating factor 1 (CSF-1) andother cytokines,
recruits and promotes a M2 phenotype in TAMs [64].
Inhibition of endogenous AR in macrophages results in
activation of CCL2/CCR2 and STAT3 and the recruit-
ment of macrophages promotes prostate cancer
metastasis [65]. Given the fact that these observations
were obtained in androgen blockade setting and αvβ6
promotes a castration resistancemechanism,wemay
further speculate that the regulatory effect of αvβ6 on
prostate cancer is partiallymediated bymacrophages.
Overall, these studies will pave the way for
innovative therapeutic approaches in prostate can-
cer which will block the transfer, or uptake of αvβ6-
containing exosomes, to monocytes. Since it is
currently believed that the epithelium-specific αvβ6
integrin functions only in cells that synthesize it,
we have now provided evidence for its ability to actired for monocyte M2 polarization in prostate cancer, Matrix Biol
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context, αvβ6 signaling has been linked to metasta-
sis and bone lesions [18], suggesting that the de-
livery of this integrin via exosomes may play a role
in transferring its related function to monocytes, and
that interfering with it, will inhibit CRPC. It may also
be speculated that, as for the αvβ3 integrin, the
bending and unbending conformational changes
of αvβ6 regulated by tensile forces exerted by the
exosome structure may affect the vesicle content
[66]. As integrins are multifunctional receptors im-
plicated in prostate cancer maintenance, we have
shown that their transfer via exosomes from prostate
cancer cells to cells in the TME may activate
signaling mechanisms important for disease pro-
gression. In turn, this may open new therapeutic
prospects for patients with advanced, metastatic
CRPC, as disruption of integrin-dependent signaling
may be expected to inhibit a host of downstream
pathways controlling survival mechanisms of pro-
tection that promote therapy-resistance. Similarly,
a recent study shows that anti-myeloma chemotherapy
enhances secretion of tumor cell exosomes, which are
rich in heparanase and regulate cytokine expression of
macrophages [67]. Future studies will reach a compre-
hensivemechanistic understanding of integrin-directed
signaling in cell-cell communication in prostate cancer
progression and open new possibilities for diagnosis
and risk stratification, as well as therapy-resistance, in
prostate cancer patients [3].Experimental procedures
Reagents and antibodies (Abs)
Lympholyte®-Mammal (Cedarlane CL5115) was
used for the isolation of PBMC and Lympholyte®-
Human (Cedarlane CL5015) was used for the
isolation of human PBMC. The resulting cell popula-
tions demonstrate a high, and non-selective recovery
of viable lymphocytes and monocytes. Optiprep
(Sigma Aldrich, 1556) was used to generate iodixanol
density gradient by ultracentrifugation.
Flow cytometry analysis was performed using the
following Abs: mouse monoclonal abs: 6.3G9 against
human and mouse αvβ6 integrin from Biogen was
described previously [14,29], Alexa Fluor 488® conju-
gated CD14 (BD Biosciences, 562,689), PE-
conjugated CD204 (BD Biosciences, 566,251), APC
conjugated CD163 (R&D Systems, 215,927). FITC
conjugated rat against mouse IgG (Biolegend,
406,605) was used as a secondary Ab. A rabbit
polyclonal Alexa Fluor 488® conjugated F(ab’)2
against mouse IgG (Thermo Scientific, A-21204) was
used also as a secondary Ab. Purified non-immune
mouse IgG (Pierce, 31,903) was used as an isotype
control.Please cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009The following Abs were used for IB analysis:
mouse monoclonal Abs: 6.2A1 against human
and mouse αvβ6 (1), CD9 (Santa Cruz, sc18869),
CD63 (Abcam, ab8219) , CD81 (Abcam,
ab23505), MX1/2/3 (Santa Cruz, sc166412).
Rabbit polyclonal Abs against: FLOT1 (Abcam,
ab41927), TSG101 (Abcam, ab30871), human and
mouse STAT1 (Santa Cruz, sc-346), ERK1 (Santa
Cruz, sc-93), CANX (Santa Cruz, sc-11,397), actin
(Sigma Aldrich, A2066). The same Ab against STAT1
(SantaCruz, sc-346)was used for immunohistochem-
istry (IHC) analysis formouse tissue.Ch2A1was used
for αvβ6 IHC on mouse tumors, as described
previously [14].
Control siRNA, D1 and D2 β6 siRNA duplexes (IDT
Incorporated) were described previously [14,29].
Cells and culture conditions
PC-3 cells, a prostate cancer cell line and THP-1
cells, a human monocyte cell line were cultured
according to American Type Culture Collection
recommendations (ATCC). PBMC isolated from
mouse and human blood were cultured as previously
described [68].
To obtain β6-EGFP PC3 and EGFP-PC3 cell lines,
PC3 prostate cancer cells (grown in RPMI supple-
mented with 10%heat-inactivated FBS and 100 U/mL
penicillin) were transfected with EGFP-N3 plasmid
(a kind gift from Dr. Fabienne Paumet, Thomas
Jefferson University) and used as negative control
or β6-EGFP-N3 plasmid having EGFP-tag in the C-
terminus of β6-cDNA on plasmid backbone (Addgene
plasmid #13593, generated by Dr. Dean Sheppard,
UCSF school of medicine, San Francisco, USA) using
the Lipofectamine 2000 reagent (Thermo Fisher
Scientific) at a ratio of 3 μL Lipofectamine/μg
of DNA. Single colonies were obtained by G418
antibiotic selection (1000 μg/mL) and expanded for
screening of GFP expression using a fluorescence
microscope. Pooled populations of stably transfected
cells were generated (β6-EGFP-PC3 and EGFP-PC3)
and confirmed for expression of β6-integrin and GFP
by IB. The PC3-shβ5 and PC3-shβ6 cells and down-
regulation of exosomal β6 Integrin using siRNA
duplexes, D1 and D2, or non-specific control siRNA
were described previously [69]. PC3-shβ5 transfec-
tants were used as control.
Human samples
Prostate cancer patient (n = 14) blood samples
were discarded specimens obtained from patients at
the Jefferson Medical Oncology Clinic. Age-matched
healthy donors (n = 5) volunteered to provide sam-
ples with written consent documented. All speci-
mens were collected in accordance with a Jefferson
IRB approved protocol, coded, and de-identified
before processing.ired for monocyte M2 polarization in prostate cancer, Matrix Biol
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Mouse blood was obtained via cardiac puncture
after euthanasia and mixed with Anticoagulant Citrate
Dextrose (ACD) Solution (1.4 g citric acid, 2.5 g
sodium citrate, 2.0 glucose per 100 mL) at 40 μL
ACD per 1 mL blood sample. The anticoagulated
blood was diluted with 1 volume of PBS then the
mixture was layered over Lympholyte®-Mammal in a
ratio of volume 4:3, followed by room temperature
centrifugation at 800 g for 30 min without brake. The
PBMC containing buffy coat were collected, washed
with PBS, and resuspended in complete media for
further processing.
PBMC were obtained from EDTA treated human
blood following the same methodology, but blood
was withdrawn via venipuncture and Lympholyte®-
Human was used in a ratio of volume 2:1. Eleven
Ptenpc−/− mice (52–80 week old) and 9 Pten wild-
type mice (40–60 week old) were used for PBMC
isolation.
Flow cytometry analysis
Flow cytometric phenotyping of murine and human
PBMC was performed as previously described [68].
All flow data were acquired using an LSR ii flow
cytometer (BD Biosciences), and were analyzed
using FlowJo® software (FlowJo, LLC).
Label-free quantitative analysis by mass
spectrometry
Equal amounts of proteins from exosome and cell
lysates were run on a 12% SDS gel for 0.5 cm and
stained with colloidal blue. Gel lanes were excised
and digested with modified trypsin (Promega).
Tryptic peptides were analyzed by LC-MS/MS on
a Q Exactive Plus mass spectrometer (Thermo
Scientific) coupled with a Nano-ACQUITY UPLC
system (Waters). Samples were injected onto a
UPLC Symmetry trap column (180 μm i.d. × 2 cm
packed with 5 μm C18 resin, Waters), and tryptic
peptides were separated by RP-HPLC on a BEH
C18 nanocapillary analytical column (75 μm i.d. ×
25 cm, 1.7 μm particle size, Waters) using a 4 h
gradient. Eluted peptides were analyzed by the
mass spectrometer set to repetitively scan m/z from
400 to 2000. The full MS scan was collected at
70,000 resolution followed by data-dependent MS/
MS scans at 17,500 resolution on the 20 most
abundant ions exceeding a minimum threshold of
20,000. Peptide match was set as preferred; exclude
isotopes option and charge-state screening were
enabled to reject single and unassigned charged
ions. MS data were analyzed with MaxQuant 1.5.2.8
software [70]. MS/MS data were searched against
the human UniProt protein database (July 2014)
using full trypsin specificity with up to two missedPlease cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009cleavages, static carboxamidomethylation of Cys,
and variable oxidation of Met, and protein N-terminal
acetylation. Consensus identification lists were gen-
erated with false discovery rates of 1% at both the
protein and peptide levels. For label-free quantita-
tion, the MaxLFQ algorithm was used and the “match
between runs” option was enabled to transfer MS/
MS identifications across LC-MS/MS runs based on
accurate mass and retention time. Unique and razor
peptides were considered for quantification and a
minimum of two ratio counts were required for each
of the normalized protein intensity. Protein tables
were filtered to remove reverse database entries,
common contaminants, and proteins identified by a
single peptide. Normalized intensity data was floored
to the minimum detected signal (intensity of 107).
Unsupervised hierarchical clustering of samples was
performed on log10-scaled intensities using nor-
malized Euclidean distance with average linkage.
Unpaired two-tail t-test was performed between
controls (NT, NS) and knockdown (D1, D2) samples
and nominal p-values were corrected for multiple
testing using Benjamini-Hochberg method to esti-
mate False Discovery Rate (FDR). Fold changes
were calculated from the mean normalized protein
intensities between the two groups. Final list of
robustly detected, most changed candidates includ-
ed affected at least 4 fold, FDR b 10% proteins
detected by at least 10 MS/MS counts and at least
10 unique peptides.
Genetically engineered mouse models
Ptenpc−/− mice were obtained from UCLA and
generated as previously described [71]. The β6-null
mice were obtained from Dr. Dean Sheppard,
University of California San Francisco [72]. Mice were
housed in pathogen-free conditions, and all work was
performed in accordance with an IACUC approved
protocol, at Thomas Jefferson University.
Exosome isolation
PC3 exosomes were isolated from serum-free cell
culture supernatant via ultracentrifugation as de-
scribed previously [29,48].
For iodixanol gradient separation, a previously
described procedure was used [47]. Pellets obtained
fromultracentrifugation of conditionedmedia fromPC3
prostate cancer cells were suspended in 1.636 mL
of 30% iodixanol solution (made by mixing 1:1 of 60%,
wt/vol) stock solution of iodixanol density gradient
medium and a buffer (0.25 M sucrose, 10 mM Tris pH
8.0, 1 mM EDTA pH 7.4) and transferred to a SW55Ti
rotor tube (Beckman). Next, 0.709 mL of 20% (wt/vol)
iodixanol and 0.654 mL of 10% (wt/vol) iodixanol were
successively layered on top of the 30% iodixanol-
vesicle suspension and tubeswere centrifuged for one
hour at 350,000 g (54,000 rpm), 4 °C, in SW55Ti rotorired for monocyte M2 polarization in prostate cancer, Matrix Biol
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0.267 mL were then collected starting from top of the
tube. Refractive index was assessed with a refractom-
eter and density calculated. All fractions were diluted
with 1 mLPBSand centrifuged for 70 min at 100,000 g
(53,000 rpm), 4 °C, in a TLA-100.2 rotor (BECKMAN,
Optima TL Ultracentrifuge). The respective pellets
thus obtained were washed in 1 mL PBS and again
centrifuged for 70 min at 100,000 g (53,000 rpm), 4 °C,
in a TLA-100.2 rotor. These concentrated fractions
were finally resuspended in 30 μL of PBS.
Exosome transfer assays
β6-null PBMC (isolated from 3β6-null mice and
pooled) and human normal PBMC, both separated
using Lympholyte, or THP1 cells were incubated
with or without PC3 derived exosomes. Cells were
collected and subjected to IB analysis for β6
levels. To evaluate exosome-mediated internaliza-
tion of β6, β6-null PBMC were resuspended with
sodium acetate buffer (0.2 M acetic acid/0.5 M
NaCl, pH 2.8) [14,29] after the incubation with
exosomes, then the cells were rinsed with PBS
and lysed for IB.
Inhibition assay and immunoblotting analysis
PC3 cells (6.0 × 105) were re-suspended in 3
mL of RPMI1640 medium, supplemented with 10
μg/mL 6.3G9, 1E6 or PBS. Cells were plated into
60 mm tissue culture dishes and incubated for 24
h, and then cells were lysed and the cell lysates
were prepared for IB analysis. IB analyses for
exosome characterization and β6 integrin expres-
sion were performed as previously described
[14,29].Imaging, Ab treatment of Ptenpc−/− mice and
immunohistochemistry analysis
Ab treatment of Ptenpc−/− Mice has been previ-
ously described [14]. Before Ab injection, mouse
tumor sizes were measured with the Vevo 2100 high
frequency, small animal, ultrasound scanner (Fuji-
film/Visualsonics, Toronto, Ontario, Canada) and a
38 MHz linear array transducer (the MS400). The
ultrasound scanning was performed by registered
sonographer. Tumor volumes were obtained by
measuring the lesion dimensions in three orthogo-
nal planes using the build-in calipers on the
scanner, and the tumor volume was calculated as
Volume = (length×width×height) × Pi/6. Ab treat-
ment of Ptenpc−/− mice was described previously
[14]. IHC was performed on murine formalin-fixed
paraffin embedded prostate tumor samples as
previously described [14]. Five mice for eachPlease cite this article as: H. Lu, et al., Exosomal αvβ6 integrin is requ
(2017), https://doi.org/10.1016/j.matbio.2018.03.009group (6.3G9 and 1E6) were analyzed. Stained
slides were scored individually.
For each tumor, 3 random invasive adenocarcino-
ma areas were scanned; the average of the percent-
age of STAT1 positive neoplastic cells acquired from
the 3 areas is shown.
NTA
NTA was performed to characterize exosome
samples based on size following a previously
established protocol [48] using NS300 (Malvern
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